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LETTERS TO THE EDITOR
Pulmonary Vascular Disease in Pregnancy
In their paper on Outcome of Pulmonary Vascular Disease in Preg-
nancy: A Systemic Overview from 1978 through 1996, Dr. Weiss and
colleagues kindly quoted me in the following sentence:
Although frequently unavoidable, caesarean section should be
considered a risk (co)factor as it is not the safest route for
delivery in parturiants with pulmonary vascular disease.
HEART (Oakley CM. Pregnancy and Congenital Heart
Disease. Heart 1997;78:12–4.
Unfortunately, the quote misrepresents my views. In my editorial, I
wrote:
Normal delivery has been favored for women with heart disease
but good arguments can be made for more frequent use of
caesarean delivery for some patients. In cyanosed women
the effort of normal delivery causes increased right to left
shunting and fetal hypoxaemia and caesarean section gives
premature babies a better chance of survival. It safeguards
mothers with little circulatory reserve by eliminating mater-
nal physical effort and expediting the birth process.
Conclusions drawn from an overview of the literature can be misleading.
The Eisenmenger patients delivered by caesarean section may have been
more severe and therefore more cyanotic, unsuitable for induction of
labor because they were more premature and at higher risk. Gleicher’s
paper published in 1979, also based on a literature review, is widely
quoted (and probably acted on) and makes the same mistake.
The authors were perhaps fortunate in not having any personal
experience with these patients (none are quoted).
CELIA M. OAKLEY, MD, FRCP, FACC
Hammersmith Hospital
Du Cane Road
London W12 ONN
United Kingdom
Better Patency With SK Than With tPA?
In the PERM retrospective study (1) of thrombolysis in acute MI,
streptokinase was associated with highly significantly better patency
rates than accelerated tPA for those treated within 3 h of symptom
onset (TIMI grade 2 or 3 patency 90 min after starting thrombolytic
therapy: SK 87% patency [152/175] vs. accelerated tPA 69% patency
[107/155], 2P , 0.0001). For patients treated later, (i.e., 4–6 h after
pain onset), the numbers were smaller and there was no significant
difference between SK and tPA (SK 59.4% [41/69] vs. tPA 69.5%
[57/82], NS). Combining both time periods, therefore, SK appeared
nonsignificantly better than accelerated tPA (SK 79% [193/244] vs.
tPA 69% [164/237], NS).
If, however, instead of combining both time periods, the second
period is subdivided even more finely into 4–5 h and 6 h, then the
patency results for the few who were treated 6 h after pain onset
appeared to favor tPA (SK 2/13 vs. tPA 13/19: the results among these
13 SK-treated patients are the sole basis for the main claims [1,2] about
the findings of this study). But, such numbers are too small to be
reliably informative, and the results in 4–5 h do not corroborate them,
indicating 70% patency with both treatments (SK 39/56 vs. tPA 44/63),
which contradicts the editorial comment (2) on patency rates in this
time period. The fitting of mathematical models may have concealed
from authors (1) and commentators (2) alike the sparseness of the
evidence from this study and the fact that, on average, the patency
results favor SK, not tPA.
Oddly, the editorial comment (2) accompanying the study chose to
report these results as if they were unfavorable to SK. Maybe that
particular inversion of reality doesn’t matter much: review (3) of
stroke-free survival in all of the big randomized trials that have
compared SK versus tPA (without restricting attention only to the
GUSTO-1 study) found no significant difference in outcome among
some 80,000 randomized patients, so the choice of thrombolytic agent
is of little relevance to public health.
In other respects, however, that editorial comment was more
dangerously misleading, for large randomized trials have in fact shown
that, irrespective of the treatment regimen, thrombolytic therapy does
significantly improve survival even for patients who present 6–12 h
after pain onset, or who are hypotensive (4).
RICHARD PETO, FRS, MRCP
RORY COLLINS, MBBS, MSc
Clinical Trial Service Unit
Nuffield Department of Clinical Medicine
University of Oxford
Oxford
United Kingdom
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Table 1. Data Extracted from the Published Report of the PERM
Retrospective Study (1)*
Hours From
Pain Onset
to
Treatment
TIMI grade 2 or 3 90-min patency
SK Accelerated tPA
1–3 152/175 (87%) 107/155 (69%)
4–5 39/56 (70%) 44/63 (70%)
6 2/13 (15%) 13/19 (68%)
Total 193/244 (79%) 164/237 (69%)
*Note: These numbers are obtained from Figure 1 in the report and match
exactly the percentages cited in the summary, which is slightly discrepant with
some of those cited in the text (1).
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